These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39556978)

  • 1. Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohort.
    van der Wel JWT; Jebbink M; van den Broek D; Steinbusch LC; Theelen WSME; Ruiter G; Buikhuisen W; Burgers JA; Baas P; Vermeulen M; van der Noort V; Hashemi SMS; Bosch LJW; Monkhorst K; Smit EF; Boelens MC; de Langen AJ
    Lung Cancer; 2024 Dec; 198():107972. PubMed ID: 39556978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac Events and Survival in Patients With EGFR-Mutant Non-Small Cell Lung Cancer Treated With Osimertinib.
    Lin CY; Chang WT; Su PL; Kuo CW; Yang J; Lin CC; Lin SH
    JAMA Netw Open; 2024 Dec; 7(12):e2448364. PubMed ID: 39636639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.
    Hibino M; Imamura Y; Shimoyama R; Fukui T; Fukai R; Iwase A; Tamura Y; Chihara Y; Okabe T; Uryu K; Okuda T; Taguri M; Minami H
    Target Oncol; 2024 Nov; 19(6):925-939. PubMed ID: 39302602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.
    Lu S; Ahn MJ; Reungwetwattana T; Özgüroğlu M; Kato T; Yang JC; Huang M; Fujiki F; Inoue T; Quang LV; Sriuranpong V; Vicente D; Fuentes C; Chaudhry AA; Poole L; Armenteros Monterroso E; Rukazenkov Y; van der Gronde T; Ramalingam SS
    Ann Oncol; 2024 Dec; 35(12):1116-1125. PubMed ID: 39289145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure-response modelling of osimertinib in patients with non-small cell lung cancer.
    Johnson M; Lin YW; Schmidt H; Sunnaker M; Van Maanen E; Huang X; Rukazenkov Y; Tomkinson H; Vishwanathan K
    Br J Clin Pharmacol; 2024 Dec; 90(12):3263-3276. PubMed ID: 39160062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of osimertinib plus bevacizumab versus osimertinib alone for advanced non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials.
    Yao L; Zhang C; Li D; Xu L; Yang X
    Medicine (Baltimore); 2024 Nov; 103(45):e40320. PubMed ID: 39533634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis.
    Priantti JN; Fujiwara Y; Aquino de Moraes FC; Michelon I; Castro C; Leighl NB; Cavalcante L; Addeo A; Bar J; Horita N; Cortellini A; Nassar AH; Vilbert M; Naqash AR
    JCO Precis Oncol; 2024 Nov; 8():e2400331. PubMed ID: 39576954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.
    Kraskowski O; Stratmann JA; Wiesweg M; Eberhardt W; Metzenmacher M; Schmid KW; Herold T; Schildhaus HU; Darwiche K; Aigner C; Stuschke M; Laue K; Zaun G; Kasper S; Hense J; Sebastian M; Schuler M; Pogorzelski M
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9243-9252. PubMed ID: 37198447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NUAK1-Mediated Phosphorylation of NADK Mitigates ROS Accumulation to Promote Osimertinib Resistance in Non-Small Cell Lung Carcinoma.
    Lin W; Wang N; Wu S; Diao M; Huang Q; Li K; Mei P; Wang X; Liao Y; Meng Y
    Cancer Res; 2024 Dec; 84(23):4081-4098. PubMed ID: 39159134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study.
    Karayama M; Suda T; Yoh K; Usui K; Hosomi Y; Kishi K; Naka G; Watanabe K; Tamano S; Uemura K; Kunitoh H
    Lung Cancer; 2024 Dec; 198():108037. PubMed ID: 39602849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT.
    Coulton S; Nizalova O; Pellatt-Higgins T; Stevens A; Hendrie N; Marchand C; Vass R; Deluca P; Drummond C; Ferguson J; Waller G; Newbury-Birch D
    Public Health Res (Southampt); 2023 Mar; 11(3):1-77. PubMed ID: 37254608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients.
    Xi Y; Bai Z; Gao S; Guo J; Zhang Z; Zhang H; Qu L; Xu B; Wang W; Shan G; Cui W; Bai W; Ji X
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8573-8580. PubMed ID: 37186065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.
    Harnan S; Kearns B; Scope A; Schmitt L; Jankovic D; Hamilton J; Srivastava T; Hill H; Ku CC; Ren S; Rothery C; Bojke L; Sculpher M; Woods B
    Health Technol Assess; 2024 Oct; 28(73):1-230. PubMed ID: 39487661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant-allele dispersion correlates with prognosis risk in patients with advanced non-small cell lung cancer.
    Wang CX; Yan J; Lin S; Ding Y; Qin YR
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):8545-8555. PubMed ID: 37093348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutations.
    Patil T; Gao D; Watson A; Sakamoto M; Nie Y; Gibson A; Dean ML; Yoder BA; Miller E; Stalker M; Aisner DL; Bunn PA; Schenk EL; Marmarelis ME; Bennati C; Navani V; Zhang Y; Camidge DR
    Lung Cancer; 2024 Nov; 199():108040. PubMed ID: 39615411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Risk Factors, and Development and Validation of Prognostic Prediction Models for Distant Metastasis in Patients With Rectal Cancer: A Study Based on the SEER Database and a Chinese Population.
    Zhang H; Wang H; Yao Y; Liu L; Feng F; Li H; Sun C
    Cancer Control; 2024; 31():10732748241303650. PubMed ID: 39579008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study.
    Han JY; Ahn MJ; Lee KH; Lee YG; Kim DW; Min YJ; Kim SW; Cho EK; Kim JH; Lee GW; Lee SS; Lee NM; Jang HW; Han H; Park H; Lee J; Cho BC
    BMC Med; 2024 Oct; 22(1):428. PubMed ID: 39379931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.